Moses Makunje
Director of Finance/CFO at NUVATION BIO INC.
Net worth: 27 803 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Hung | M | 66 | 6 years | |
| Kim Blickenstaff | M | 71 | 5 years | |
| Kathryn Falberg | F | 63 | 4 years | |
| Robert D. Mashal | M | - | - | |
| Tony Vernon | M | 68 | 5 years | |
| Robert Bazemore | M | 56 | 4 years | |
| Jonathan Lim | M | 52 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 5 years |
| Kerry Wentworth | F | 51 | 2 years | |
| Daniel Welch | M | 66 | 4 years | |
| Richard Scheller | M | 70 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 5 years |
| Gary Hattersley | M | 57 | 5 years | |
| Stacy Markel | F | 59 | 5 years | |
| David Hanley | M | 54 | 3 years | |
| Dong Fang Liu | M | 54 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Oleg Nodelman | M | 47 | 2 years | |
| Jennifer Fox | F | 53 | 3 years | |
| Lisa V. DeLuca | M | - | - | |
| Thomas S. Templeman | M | 64 | 2 years | |
| Sergey Yurasov | M | 55 | 3 years | |
| Michelle Doig | F | 50 | 2 years | |
| Alex Colville | M | - |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 21 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Moses Makunje
- Personal Network
